A decade of cell death studies: Breathing new life into necroptosis

Imran Khan; Abdelrahman Yousif; Mikhail Chesnokov; Linda Hong; IIana I. Chefetz

doi:10.1016/j.pharmthera.2020.107717

A decade of cell death studies: Breathing new life into necroptosis

Imran Khan, Abdelrahman Yousif, Mikhail Chesnokov, Linda Hong, IIana I. Chefetz

Hormel Institute

Research output: Contribution to journal › Review article › peer-review

76 Scopus citations

Abstract

Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance.

Original language	English (US)
Article number	107717
Journal	Pharmacology and Therapeutics
Volume	220
DOIs	https://doi.org/10.1016/j.pharmthera.2020.107717
State	Published - Apr 2021

Bibliographical note

Funding Information:
This work was supported in part by the Michigan Ovarian Cancer Alliance (MIOCA) , the Liz Tilberis early career OCRA award, the Marsha Rivkin Ovarian Center pilot award , the Elsa U. Pardee foundation , and the WeRoc research grant from Foundation for Women's Cancer (to I.C.)

Publisher Copyright:
© 2020 Elsevier Inc.

Keywords

Cancer
Cardiovascular disorders
Cell death
Cell programmed necrosis
MLKL
Necroptosis
Neurodegenerative diseases
RIPK1
RIPK3

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.pharmthera.2020.107717

OpenUrl availability

Full text

Cite this

@article{a288b18198c84a0ca62c299bc5fec352,

title = "A decade of cell death studies: Breathing new life into necroptosis",

abstract = "Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance.",

keywords = "Cancer, Cardiovascular disorders, Cell death, Cell programmed necrosis, MLKL, Necroptosis, Neurodegenerative diseases, RIPK1, RIPK3",

author = "Imran Khan and Abdelrahman Yousif and Mikhail Chesnokov and Linda Hong and Chefetz, {IIana I.}",

note = "Funding Information: This work was supported in part by the Michigan Ovarian Cancer Alliance (MIOCA) , the Liz Tilberis early career OCRA award, the Marsha Rivkin Ovarian Center pilot award , the Elsa U. Pardee foundation , and the WeRoc research grant from Foundation for Women's Cancer (to I.C.) Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = apr,

doi = "10.1016/j.pharmthera.2020.107717",

language = "English (US)",

volume = "220",

journal = "Pharmacology and Therapeutics",

issn = "0163-7258",

}

TY - JOUR

T1 - A decade of cell death studies

T2 - Breathing new life into necroptosis

AU - Khan, Imran

AU - Yousif, Abdelrahman

AU - Chesnokov, Mikhail

AU - Hong, Linda

AU - Chefetz, IIana I.

N1 - Funding Information: This work was supported in part by the Michigan Ovarian Cancer Alliance (MIOCA) , the Liz Tilberis early career OCRA award, the Marsha Rivkin Ovarian Center pilot award , the Elsa U. Pardee foundation , and the WeRoc research grant from Foundation for Women's Cancer (to I.C.) Publisher Copyright: © 2020 Elsevier Inc.

PY - 2021/4

Y1 - 2021/4

N2 - Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance.

AB - Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance.

KW - Cancer

KW - Cardiovascular disorders

KW - Cell death

KW - Cell programmed necrosis

KW - MLKL

KW - Necroptosis

KW - Neurodegenerative diseases

KW - RIPK1

KW - RIPK3

UR - http://www.scopus.com/inward/record.url?scp=85095810425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85095810425&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2020.107717

DO - 10.1016/j.pharmthera.2020.107717

M3 - Review article

C2 - 33164841

AN - SCOPUS:85095810425

SN - 0163-7258

VL - 220

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

M1 - 107717

ER -

A decade of cell death studies: Breathing new life into necroptosis

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this